Ductal Carcinoma in Situ (DCIS) Treatment — The Latest Approaches and Who Needs What
In this article
Introduction: Ductal carcinoma in situ (DCIS) represents a group of neoplastic lesions confined to the breast ducts and lobules, without crossing the basement membrane, but heterogeneous in histological appearance and biological potential. With widespread screening mammography, this once-rare entity has become central to breast cancer diagnosis. The primary goal of DCIS management is to prevent progression to invasive carcinoma. The first section of this series details epidemiological data, imaging findings, and histopathological assessment criteria.
1. Epidemiology: Why Is Incidence Increasing?
Increasing Incidence (per 100,000 Women)
New DCIS Cases
(~25% of all breast cancers)
Etiology and Risk Factors
The risk profile of DCIS largely overlaps with that of invasive cancer.
- ▸
Age: Incidence increases with age. It is rare below age 30.
(Ages 40-49: 0.6/1000 → Ages 70-84: 1.3/1000) - ▸
Genetic Predisposition: Every patient diagnosed with DCIS should be assessed for genetic counseling.Clinical Pearl: In particular, BRCA1/2 mutations can directly change treatment (such as mastectomy instead of breast-conserving surgery or preventive surgery on the opposite breast).
- ▸
Other Factors: Family history, nulliparity (never having given birth), older age at first birth, obesity, and high breast density.
2. Clinical Features and Imaging Findings
More than 90% of patients are asymptomatic in clinical practice. A palpable mass, nipple discharge, or Paget disease (an eczema-like lesion of the nipple) is less common. The diagnostic process usually begins with imaging.
GOLD STANDARD Mammography
In 75% of cases, diagnosis follows suspicious microcalcifications. Calcification morphology may suggest pathological grade:
Magnetic Resonance Imaging (MRI)
Typically seen as “Non-mass enhancement” . Distribution may be ductal, linear, or segmental.
Correlation with pathological size is significantly higher than for mammography (72% vs 56%). Valuable for detecting multifocality in surgical planning.
3. Biopsy Methods and Pathological Assessment
Clinical Pearl: Why Not FNA?
For assessing microcalcifications, Stereotactic Vacuum-Assisted Core Biopsy is the gold standard. Fine-Needle Aspiration (FNA) is contraindicated. FNA shows only cells (cytology), not basement membrane integrity. It therefore cannot distinguish DCIS from invasive cancer.
- Low: Uniform, small nuclei. Slow growth pattern.
- Intermediate: Transitional form.
- High: Pleomorphic, large, irregular nuclei. High genetic instability and recurrence risk.
Necrosis indicates rapid cell turnover.
Prognostic Genomic Tests
Advanced molecular tests used to decide whether to omit radiotherapy (de-escalation) after breast-conserving surgery (lumpectomy):
Estimates the risk of invasive recurrence over 10 years after lumpectomy. Supports omitting radiotherapy in low-score patients, even when they appear clinically intermediate-risk.
Predicts both invasive and DCIS recurrence after breast-conserving surgery. Low-score patients tend not to derive significant benefit from radiotherapy.
4. Differential Diagnosis and Histological Spectrum
When diagnosing DCIS, distinguishing it from benign proliferative lesions (ADH) and invasive carcinoma is vital. An invasive focus may be found after surgery in 20% of those diagnosed with DCIS on core biopsy (upstaging).
| Lesion | Defining Features | Difference in Management |
|---|---|---|
| Atypical Ductal Hyperplasia (ADH) | Has cytological features similar to low-grade DCIS, but measures < 2 mmor does not completely fill the duct (partial involvement). | Surgical excision recommended (10-25% may progress to DCIS/invasive cancer). |
| Lobular Carcinoma in Situ (LCIS) | Arises from terminal duct lobules; E-cadherin loss (discohesion) is typical. | Usually incidental. Surgery is not mandatory for the classic type (a high-risk marker); the pleomorphic type requires surgery. |
| Microinvasive Carcinoma | Invasion beyond the basement membrane, with the largest focus measuring ≤ 1 mm . | Considered stage T1mi. Managed like invasive cancer (SLNB, systemic treatment). |
Staging (AJCC 8th Edition)
Because DCIS is confined within the ducts, nodal or distant metastasis is not expected.
1. Local Treatment: Surgical Options and Criteria
Surgery is the cornerstone of DCIS treatment. The goal is to remove the lesion with negative margins. The decision between breast-conserving therapy (BCT) and mastectomy depends on tumor biology and patient preference.
FIGURE 1: Surgery and Axillary Management Algorithm
Tumor Size, Multicentricity, Breast Size, Genetics (BRCA), Patient Preference, RT Contraindication
Breast-Conserving Surgery (Lumpectomy)
- ✅ Surgical Margin: Target ≥ 2mm clear margin.
- ❌ Axilla: Routine SLNB is not performed.
- *Considered only for high-risk patients or those who may require conversion to mastectomy.
Total Mastectomy
- ✅ Indication: Multicentric disease, Extensive Area, Repeated Positive Margins.
- ⚠️ Axilla: SLNB is MANDATORY.
- *Lymphatic mapping cannot be performed after breast tissue is removed.
A. Breast-Conserving Therapy (BCT)
Equivalent to mastectomy in survival (98% cure). Superior cosmetic outcomes.
Eligibility:- Unifocal (single-focus) disease.
- Appropriate tumor-to-breast size ratio.
- Ability to achieve negative surgical margins.
B. Mastectomy
Lowest local recurrence risk (1%). Usually performed with reconstruction.
Required When:- Multicentric (multiple-focus) disease.
- Repeated positive margins.
- Radiotherapy is contraindicated (pregnancy, vasculitis, etc.).
Critical Surgical Nuances
When RT Is Planned: A clear margin of 2 mm is considered sufficient (SSO/ASTRO Guideline).
If RT Will Not Be Given: Without RT's protective effect, a wider margin should be targeted (> 1 cm according to some experts).
Mastectomy: SLNB should be performed (cannot be accessed later).
Lumpectomy (BCT): Routine SLNB is not recommended. It is performed in a 2nd procedure only if pathology reveals an invasive focus.
2. Radiotherapy: Who Needs It, and Who Can Omit It?
Whole-breast radiotherapy (WBRT) after BCT reduces invasive and in-situ recurrence by 50%, but no overall survival contribution has been demonstrated. RT omission is therefore a safe option in the “Low-Risk” group.
3. An Emerging Treatment: Cryoablation
Cryoablation (tumor freezing), investigated as a minimally invasive alternative to surgery, is not standard care. It is promising in selected cases or clinical trials. Patient selection is critical.
✅ Suitable Candidate Profile (Inclusion)
- • Small Size: ≤ 1.5 cm (maximum 2.0 cm).
- • Unifocal: Single-focus disease.
- • Imaging: A lesion with clear boundaries visible on ultrasound.
- • Biology: Low/Intermediate Grade, ER/PR-Positive, HER2-Negative.
- • Clinical: Patients at high surgical risk (older age, comorbidities) or who decline surgery.
❌ Unsuitable (Exclusion)
- • High Grade: Grade 3 lesions.
- • Necrosis: Comedo necrosis present.
- • Extent: Multicentric or extensive disease.
- • Location: Lesions very close to the skin or pectoral fascia (risk of cold injury).
- • Imaging: Lesions seen only as calcifications and not identifiable on ultrasound.
4. Systemic Endocrine Treatment
75% of DCIS lesions are hormone receptor (ER)-positive. Endocrine treatment is recommended for 5 years to reduce ipsilateral recurrence and new contralateral cancer.
FIGURE 2: Adjuvant Endocrine Treatment Decision Algorithm
No Treatment
5 Years of Treatment
- Dose: 20 mg/day.
- Target: Pre- and postmenopausal patients.
- Effect: Reduces invasive recurrence by 30-50% (NSABP B-24).
- Target: Postmenopausal patients only.
- Advantage: More effective than Tamoxifen in postmenopausal women younger than 60 (NSABP B-35).
- Dose: 5 mg/day.
- Indication: Patients unable to tolerate the standard dose because of side effects.
- Effect: Reduces recurrence by 50% with minimal side effects (TAM-01).
5. Follow-Up and Lifestyle Management
Lifestyle (A Holistic Approach)
Obesity (BMI > 30) increases recurrence risk through inflammation and increased estrogen, particularly in postmenopausal patients. Target BMI < 25 kg/m².
At least 150 minutes of moderate aerobic exercise (brisk walking) per week is recommended.
A Mediterranean-style diet and limited alcohol (< 1 glass per day) are recommended.
Clinical Follow-Up Schedule (NCCN 2025)
- Physical Examination: Every 6-12 months for the first 5 years, then annually.
- Mammography (After BCT): First assessment 6-12 months after treatment ends, then annually.
- Mammography (After Mastectomy): Only the opposite breast is monitored annually.
- Contraindicated: Routine systemic screening (PET-CT, tumor markers) is not recommended in asymptomatic patients.
Selected Recent and Important References
- American Cancer Society. Cancer Facts and Figures, 2025.
- Hwang ES, Hyslop T, Lynch T, et al. Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial. JAMA 2025; 333:972.
- Ryser MD, Thomas SM, Li Y, et al. Cancer outcomes in women without upfront surgery for ductal carcinoma in situ: observational cohort study. BMJ 2025; 390:e083542.
- van Seijen M, Lips EH, Fu L, et al. Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. Br J Cancer 2021; 125:1443.
- Giannakeas V, Sopik V, Narod SA. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Netw Open 2018; 1:e181100.
- Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20:691.
- Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 2016; 387:849.
- Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011; 12:21.
- Solin LJ, Gray R, Hughes LL, et al. Surgical Excision Without Radiation for Ductal Carcinoma In Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.